الفهرس 
Anatomy of the liverOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
PET/CT is superior to PET and CT alone, and/or magnetic resonance imaging (MRI),in the diagnosis and treatment of various primary or metastatic cancers. Thus, PET/CT is a more accurate test than either of its individual components.
PET/CT has advantage over other imaging method, it can differentiate benign from malignant lesions ,staging ,and restaging tumor ,detect functional changes before there is any changes in clinical or radiological size of mass ,better in identify cancer that has spread ,making up treatment plane and monitoring tumor response ,detect tumor recurrence early and distinguish viable metabolically active tissue from scars.
PET/CT over CT has been attributed to the ability of FDG-PET to detect metabolic abnormalities that precede the morphologic changes seen by CT.
Currently, positron emission tomography/computer tomography (PET/CT) are more and more widely available and their application with 18F-fluorodeoxyglucose (18F-FDG) in oncology has become one of the standard imaging modalities in diagnosing and staging of tumors, and monitoring the therapeutic efficacy in hepatic malignancies. It is more sensitive and specific than PET, with a lower false-positive and false-negative rate.
The ability of PET and PET/CT with 18F-FDG to enhance the diagnostic algorithm of hepatic malignancies, which can benefit the patients suffering from hepatic metastases, HCC and CC by more accurate diagnosis, staging, restaging and further evaluation of their biologic characteristics.
Whole body positron emission tomography with (18F-Flurodeoxy-glucose (FDG) in combination with CT scanning (PET/CT) represents one of the most sensitive imaging modalities for the detection of hepatic metastases and extrahepatic tumor manifestation.
PET/CT is particularly indicated for restaging in patients with suspected recurrent and metastatic disease.
PET and PET/CT is very important in patients with unexplained high levels of tumor markers.
18F-FDG PET/CT appears to be a reliable technique for evaluating the veins of the portal system thrombus, and can be helpful in discriminating between benign and malignant portal vein thrombi.
The main limitations of 18-FDG PET and PET/CT are cost, motion artifact, attenuation correction artifact, CT artifacts and radiation exposure.